Novavax (NVAX)
(Delayed Data from NSDQ)
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $12.26 -0.06 (-0.49%) 8:24 AM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.32 USD
-0.31 (-2.45%)
Updated Oct 1, 2024 04:00 PM ET
Pre-Market: $12.26 -0.06 (-0.49%) 8:24 AM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Zacks News
Hedge Fund Diaries: Who Was Buying Your Stocks?
by Kevin Cook
SEC 13Fs reveal trades from months ago, but also patterns of long-term bullish behavior.
Are Stocks Too Hot to Buy?
by Tracey Ryniec
Lots of investors chased the big gains in the WSB/Reddit trades, but those stocks aren't the only ones that are soaring. How do you keep your cool in this red-hot market?
Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA
by Zacks Equity Research
Zacks Market Edge Highlights: GameStop, AMC Entertainment, Chipotle, Novavax and NVIDIA
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More
by Zacks Equity Research
Earnings of leading biotechs like Amgen (AMGN) and Vertex (VRTX) and vaccine updates from Novavax (NVAX) were some of the highlights of the biotech sector last week.
Novavax (NVAX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Novavax (NVAX) closed at $264.41 in the latest trading session, marking a -1.45% move from the prior day.
6 ETFs You May Love to Buy for February
by Sanghamitra Saha
February is not known for good stock returns. However, this year could be different as global economies and corporates will strive hard to register a fast rebound from the COVID-19 slump.
Top-Performing ETFs of Last Week
by Sanghamitra Saha
Simple profit-booking and some warnings from the too-big-to-fail companies probably led to crash in Wall Street last week.
Novavax (NVAX) ETFs to Rise on Impressive Coronavirus Vaccine Update
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.
Novavax's (NVAX) COVID-19 Vaccine 89.3% Effective in U.K. Study
by Zacks Equity Research
Novavax's (NVAX) COVID-19 vaccine candidate, NVX-CoV2373, proves its vaccine efficacy of 89.3% in late-stage study in the United Kingdom. Stock rises in after-hours trading.
Markets Bounce Back; Visa (V) Beats, Mondelez (MDLZ) Meets
by Mark Vickery
The Dow, which reached +650 points at its intra-day high, closed up 300 points, or around 1%. The S&P 500 followed suit, finishing up +37 points.
AstraZeneca's (AZN) Enhertu Gets FDA Nod for Gastric Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Enhertu is the first HER2-directed medicine approved in a decade for patients with HER2-positive metastatic gastric cancer.
Novavax (NVAX) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Novavax (NVAX) closed at $127.43, marking a -1.96% move from the previous day.
Orchard (ORTX) Gets FDA's RMAT Status for Gene Therapy in MLD
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy status on Orchard Therapeutics' (ORTX) investigational gene therapy, OTL-200, for treating early-onset metachromatic leukodystrophy. Shares up.
Make a Fortune With These 4 High Earnings Yield Picks
by Rimmi Singhi
While comparing stocks, if other factors are similar, investors can look out for the one with higher earnings yield. Stocks including GM, WGO, NVAX and MT score high in that parameter.
3 Biotech Stocks Poised to Outperform Amid Coronavirus Pandemic
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position NVAX, HALO and BPMC to outperform.
ERYTECH Pharma (ERYP) Catches Eye: Stock Jumps 7.4%
by Zacks Equity Research
ERYTECH Pharma (ERYP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Is the Options Market Predicting a Spike in Novavax (NVAX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Novavax (NVAX) stock based on the movements in the options market lately.
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View
by Zacks Equity Research
Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.
3 Biotech Stocks Worth Adding to Your Portfolio in 2021
by Ekta Bagri
We highlight a few biotech companies, which outperformed the sector in 2020 and are likely to witness a winning run in the near term.
Biotech Stock Roundup: REGN Provides COVID-19 Updates, MYOV Partners With PFE & More
by Zacks Equity Research
The biotech sector was in focus last week with COVID-19 vaccine study update from Novavax (NVAX) and antibody cocktail treatment update from Regeneron (REGN).
Novavax (NVAX) Initiates Phase III Study on COVID-19 Vaccine
by Zacks Equity Research
Novavax (NVAX) initiates phase III study on its coronavirus vaccine, NVX-CoV2373, in the United States and Mexico.
6 Biotech/Drug Stocks Up Manifold in 2020 Thanks to COVID-19
by Zacks Equity Research
We discuss six biotech/drug stocks, NVAX, VXRT, MRNA, TBIO, INO and BNTX that have more than doubled in 2020 on the back of their progress in coronavirus vaccine development.
4 Small COVID-19 Vaccine Makers to Look Out for in 2021
by Kinjel Shah
Here we discuss four small biotech companies, NVAX, CVAC, VXRT and ARCT, that are making COVID-19 vaccine candidates, which may be approved in 2021, if successfully developed, and bring profits.
Why Is Novavax (NVAX) Up 52.6% Since Last Earnings Report?
by Zacks Equity Research
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.